RxDoctor Payments Data

Jason Ackerman, MD

Addiction Medicine · Sheridan, WYNPI 1396060604

Payments from drug & device makers

$1,198in general payments, 2019–2025

Across 69 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$243
  • Novo Nordisk$216
  • Alkermes, Inc.$97
  • AstraZeneca$65
  • Otsuka America Pharmaceutical, Inc.$64
  • Amgen$59
  • plus $454 from 16 others

What the payments were for

  • Food & beverage$1,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few addiction medicine providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,534
Medicare patients
46
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$38,048
SuboxoneBuprenorphine Hcl/Naloxone Hcl34$11,900
OzempicSemaglutide11$10,587
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl88$9,943
Tresiba Flextouch U-200Insulin Degludec15$7,005
Buprenorphine16$2,340
Gabapentin87$1,495
Naltrexone Hcl19$662
Pantoprazole Sodium41$448
Celecoxib14$335
Lurasidone Hcl12$305
Pregabalin15$259
Tamsulosin Hcl18$221
Bupropion XlBupropion Hcl41$207
Mirtazapine18$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$23$38,04814 claims
Novo NordiskOzempic$216$10,58711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other addiction medicine in Sheridan

Where these figures come from

Is this you, or does something look wrong? →